Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J 
Welcome,         Profile    Billing    Logout  

1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
2018-004532-30: A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015 Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs).

Not yet recruiting
3
180
Europe
1092mg paliperidone palmitate extended release suspension for injection (eq. 700 mg paliperidone), 1560 mg paliperidone palmitate extended release suspension for injection (eq. 1000 mg paliperidone), R092670, Prolonged-release suspension for injection in pre-filled syringe
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA, Janssen-Cilag International NV
Schizophrenia, Schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 

Download Options